vVardis IPO prices at $18, below its $21 to $24 range
vVardis IPO: the Swiss dental company priced its New York listing at $18 a share, below the $21 to $24 range it planned, and raises about $175 million.
Evento: 13 de noviembre de 2026
Fuente primaria: 13 de noviembre de 2026
Publicado aquí: 14 de noviembre de 2026 a las 12:07 UTC
Leer: 3 min
Qué pasó
vVARDIS Holding AG, a dental company from Zug, Switzerland, priced its IPO at $18.00 per Class A share. The offering is 9,722,223 shares, which raises about $175 million. The planned range was $21 to $24. Trading on the NYSE under the ticker VVVV was due to start on November 13. Closing is expected on or about November 16.
Por qué te importa
The price landed below the range, and the company still loses money: a $27.8 million net loss in the first half of 2026, according to blue News. The targeted market value fell from up to $4.37 billion to about $3.28 billion.
Qué revisar y vigilar
Whether the deal closes on schedule and whether the underwriters use their option for 1,458,333 more shares. For trading, check a live market page. This is not investment advice.
Dónde está pasando
LIVEArrastra para girar. Puntos verdes: la bolsa está operando ahora mismo (horario normal, sin contar festivos). Sombra: donde ahora es de noche. Fronteras: Natural Earth, terremotos: USGS. Idea de las capas: God’s Eye View (MIT).
Vuelos: lo que ven ahora los receptores ADS-B voluntarios de adsb.lol (ODbL), cada minuto. Hay pocos receptores sobre océanos y zonas remotas; los aviones militares y privados a menudo no aparecen.
What was announced. On November 13, 2026, vVARDIS Holding AG said it priced its initial public offering at $18.00 per Class A ordinary share. The deal covers 9,722,223 shares. The underwriters can buy up to 1,458,333 more within 30 days. The shares were expected to start trading on the New York Stock Exchange that day under the symbol VVVV. Closing is expected on or about November 16.
Price against plan. On November 6, Renaissance Capital reported planned terms: about 9.5 million shares at $21 to $24, to raise $214 million. The final price is below that range. blue News says the deal brings in about $175 million and that the targeted market capitalization fell from up to $4.37 billion to about $3.28 billion. Renaissance Capital put the value at $1.3 billion at the midpoint of the old range. The sources do not explain how each figure is counted, so treat them as separate measures.
The company. vVardis, from Zug, was founded in 2020. Its Curodont treatment for early-stage cavities is peptide-based and applied in a dental office in five minutes or less, with no drilling or needles. In the US it sells only through Henry Schein, and its US product brings most of the revenue. Revenue was $50 million for the 12 months ended June 30, 2026. The founders are the sisters Haley and Goly Abivardi, known from the dental chain Swiss Smile.
The numbers behind the price. The company is growing but still loses money. In the first half of 2026 it reported a net loss of $27.8 million and an operating cash outflow of $16.3 million. Last year's loss was $56.4 million, according to swissinfo. At the end of 2025 it had loans of $103 million, with interest of up to 16% on part of the debt. Repayments fall due in 2027 and 2030.
Who keeps control. The founders plan to stay in charge. Swissinfo says their higher-voting shares give them 87% of the voting rights. Swissinfo notes that outside shareholders share the risk while the sisters keep full control of the company's direction.
What you can do. If you follow IPOs, read the final prospectus on the SEC website and its risk factors, not only the headlines. We do not report first-day trading figures: the pages we could open were not consistent. This is not advice to buy or sell.
Hechos confirmados
- vVARDIS Holding AG priced its initial public offering of 9,722,223 Class A ordinary shares at $18.00 per share.[1][2]
- The underwriters have a 30-day option to buy up to 1,458,333 more Class A shares at the IPO price.[1][2]
- The shares were expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol VVVV.[1][2]
- Closing of the offering is expected on or about November 16, 2026, subject to customary conditions.[1]
- Goldman Sachs and J.P. Morgan are the joint bookrunning managers; William Blair, UBS Investment Bank and Deutsche Bank Securities are bookrunners.[1]
- The registration statement on Form F-1 was declared effective by the US Securities and Exchange Commission on November 12, 2026.[1]
- A price range of $21 to $24 had been planned.[2][4]
- blue News says the offering brings in about $175 million.[2]
- blue News says the targeted market capitalization fell from an initial estimate of up to $4.37 billion to about $3.28 billion.[2]
- On November 6, Renaissance Capital reported planned terms of about 9.5 million shares at $21 to $24, to raise $214 million, with a market value of $1.3 billion at the midpoint of the range.[4]
- vVardis was founded in 2020 and treats tooth decay without drilling.[2][4]
- Its Curodont treatment for early-stage cavities is peptide-based and applied in a dental office in five minutes or less, with no drilling or needles.[4]
- In the US, the company sells exclusively through Henry Schein, and its US product generates the vast majority of revenue.[4]
- vVardis booked $50 million in revenue for the 12 months ended June 30, 2026.[4]
- In the first half of 2026 the company reported a net loss of $27.8 million and a cash outflow of $16.3 million from operating activities.[2]
- Last year's loss was $56.4 million, according to swissinfo.[3]
- At the end of 2025 vVardis had outstanding loans of $103 million, with interest of up to 16% on part of the debt, due for repayment in 2027 and 2030.[3]
- Founders Haley and Goly Abivardi intend to keep control after the IPO; swissinfo says their higher-voting shares give them 87% of the voting rights.[2][3]
- About 95% of vVardis revenue comes from the US and 2% from Switzerland.[3]
Implicaciones
- ConfirmadoThe IPO priced below the planned range, so the company raises about $175 million instead of the $214 million planned in the early terms.
- Nuestra lecturaWith losses and loans due in 2027 and 2030, the company depends on continued growth or new funding. This is our reading of the figures, not a forecast.
Todavía no se sabe
- How the shares traded on the first day. The page we opened that cites numbers is not consistent, so we leave them out.
- How the valuation is counted: Renaissance Capital gave $1.3 billion at the midpoint of the range, blue News gave about $3.28 billion at the final price.
- Whether the underwriters will use their option for 1,458,333 more shares.
- How much of the proceeds will go to repay debt. The pages we opened do not say.
A quién afecta
Switzerland, US, World. People who follow IPOs, readers interested in Swiss companies and healthcare stocks
Fuentes
- Business Wire (via Yahoo Finance): vVARDIS Announces Pricing of Initial Public Offering 13 de noviembre de 2026 · oficial
- blue News (Keystone-SDA): Vvardis is going public on the U.S. stock market at a lower price than planned 13 de noviembre de 2026 · medios
- SWI swissinfo.ch (SRF): 'Swiss Smile' sisters set sights on multi-billion-dollar IPO on Wall Street 13 de noviembre de 2026 · medios
- Renaissance Capital: Cavity treatment provider vVardis sets terms for $214 million US IPO 6 de noviembre de 2026 · medios
Portada: Gráfico de Freekonomist, una imagen simbólica, no una foto del evento. Esta es una explicación de noticias, no asesoramiento financiero.
Más historias
Frühstart-Rente: Germany backs 10 euros a month for every child
Frühstart-Rente, Germany's early start pension for children, cleared the Bundesrat on November 20. The state will pay 10 euros a month into a retirement account in the child's name, invested in the capital market.
UK retail sales rise 0.7% as shoppers stock up on tinned food
British shoppers bought 0.7% more in October than in September. Supermarkets say people are stocking up on tinned food and long-life milk after the government's 'Be Ready' campaign.
VanEck drops Gemini as custodian for its bitcoin, ether and Solana ETFs
VanEck is ending its deals with Gemini, which holds coins for its bitcoin, ether and Solana ETFs. From February 16, 2027 only Coinbase will be custodian.
Morning brief by email
The night's key moves and what matters today, in 2 minutes. One-click unsubscribe.